IXICO Wins £1.3m Neuroscience Imaging Contracts in Alzheimer’s and Huntington’s Trials

IXICO plc ( (GB:IXI) ) has provided an announcement.

IXICO plc has secured a new contract and a clinical trial extension worth a combined £1.3 million over two years, underscoring its growing role in neurological drug and diagnostics development. The company will supply amyloid PET imaging analytics to support validation of a new blood-based Alzheimer’s disease biomarker test for a major diagnostics and life sciences client, aiming to support its path toward regulatory clearance.

In parallel, IXICO has extended an existing Phase 2 Huntington’s disease clinical trial with a leading global pharmaceutical company, adding three additional analysis approaches to the study. Management said the deals reinforce IXICO’s strategy of expanding its footprint in broader central nervous system indications such as Alzheimer’s while maintaining leadership in rare neurodegenerative diseases, and of moving into higher-value, later-stage clinical development work, a trajectory that could strengthen its competitive position in CNS precision medicine.

Spark’s Take on IXI Stock

According to Spark, TipRanks’ AI Analyst, IXI is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and very bearish technicals (below key moving averages with negative MACD). A positive offset comes from supportive earnings-call guidance and order book growth, but valuation remains constrained by the company’s loss-making profile.

To see Spark’s full report on IXI stock, click here.

More about IXICO plc

IXICO plc is a London-based neuroscience imaging and biomarker analytics specialist that operates as an imaging contract research organisation for global pharmaceutical, biotechnology and diagnostics companies. Using a proprietary AI-driven platform, it supports neurological clinical trials in diseases such as Alzheimer’s, Huntington’s and Parkinson’s, providing end-to-end imaging services and biomarker analysis to advance drug and diagnostics development.

Average Trading Volume: 154,084

Technical Sentiment Signal: Sell

Current Market Cap: £18.53M

See more insights into IXI stock on TipRanks’ Stock Analysis page.